Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02907944 · ClinicalTrials.gov registry record · NA
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 3,838
- Enrollment target
NCT02907944: Completed NA study, sponsored by Yale University.
NCT02907944 is a NA study that has completed, run by Yale University. The registered enrollment target is 3,838 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02907944, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,838 participants
- Enrollment target
Study Summary
Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction treatments) were routinely provided in HIV clinics? Implementation Facilitation is an established strategy to increase the uptake of evidence-based treatments. Our goal is to evaluate the impact of Implementation Facilitation on the use of addiction treatments in four large HIV clinics. The purpose of the WHAT-IF study is: Aim 1. Among key stakeholders, to use quantitative and qualitative (mixed) methods to identify the site-specific evidence, context and facilitation-related barriers and facilitators to the integration of addiction treatments to help tailor an Implementation Facilitation for each clinic. Aim 2. To evaluate the impact of Implementation Facilitation on: 2a: Organizational readiness to deliver addiction treatments 2b: Provider readiness to deliver addiction treatments 2c: Provision of addiction treatments 2d: Changes in organizational models of care used to deliver addiction treatments Aim 3. To evaluate the impact of Implementation Facilitation on antiretroviral therapy receipt, HIV viral suppression, VACS Index, and retention in HIV care among patients eligible for addiction treatment.
Primary Outcome
Study team will use the electronic health record (EHR) to identify prescriptions for each of the target medications in the surveillance period. Study team will use CPT codes to determine whether specific counseling therapies were provided. Patients diagnosed with Opioid Use Disorder and/or Alcohol Use Disorder and/or Tobacco Use Disorder were identified and then assessed in the EHR to determine if medication assisted therapy was provided by a provider during the 6 month Intervention period.
Interventions
- BEHAVIORAL Implementation Facilitation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,838 participants |
| Start Date | 2016-09 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
What the finished NCT02907944 record still lists
NCT02907944 is an interventional study that assigns participants to a tested intervention. Its 3,838 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 1 intervention - of which Implementation Facilitation is the first listed.
NCT02907944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02907944 about?
NCT02907944 is a clinical study titled "Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation". Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction treatments) were routinely provided in HIV clinics? Implementation Facilit...
What is the current status of trial NCT02907944?
This trial is currently completed. It is a NA study. The enrollment target is 3,838 participants. The study started on 2016-09. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02907944?
The interventions under investigation include: Implementation Facilitation (BEHAVIORAL).
Who is sponsoring clinical trial NCT02907944?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02907944's enrollment target sits among peer trials
3,838 36th of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia